Addex Therapeutics Ltd (ADXN.SW)
Swiss · CHF · Healthcare · Biotechnology
CHF 0.0208 (-5.45%) as of
Key statistics
- Market cap
- 4.37M
- Forward P/E
- -0.52
- EPS (TTM)
- -0.0500
- Dividend yield
- 0.00%
- 52-week range
- 0.0180 – 0.0690
- Beta
- 2.02
- Revenue (TTM)
- 83.07k
- Profit margin
- 0.00%
- Volume
- 123.46k
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Geneva, Switzerland
- Employees
- 3
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.